Images List Premium Download Classic

Fatty Liver

Fatty Liver-related patent applications - as published by the U.S. Patent and Trademark Office (USPTO).


loading
Adenovirus ad36 e4orf1 protein for prevention and treatment of non-alcoholic fatty liver disease
Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College
November 30, 2017 - N°20170340699

This invention generally relates to methods for treating or preventing the symptoms of non-alcoholic fatty liver disease, methods for reducing excessive fat from the liver, methods of improving glycemic control, and methods for treating or preventing liver dysfunction, that comprise administering a therapeutically effective amount of adenovirus 36 e4orf1 protein or functional variant thereof.
Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof
Alnylam Pharmaceuticals, Inc.
November 30, 2017 - N°20170340661

The present invention relates to rnai agents, e. G., double stranded rnai agents, targeting the patatin-like phospholipase domain containing 3 (pnpla3) gene, and methods of using such rnai agents to inhibit expression of a pnpla3 gene and methods of treating subjects having nonalcoholic fatty liver disease (nafld) and/or a pnpla3-associated disorder.
Novel mitochondrial uncouplers for treatment of metabolic diseases and cancer
Alnylam Pharmaceuticals, Inc.
November 23, 2017 - N°20170334869

The present disclosure relates to benzamide compounds, prodrugs of the compounds, pharmaceutical compositions containing the compounds and/or the prodrugs and methods of using the compounds, prodrugs and pharmaceutical compositions in the treatment of diseases related to lipid metabolism including diabetes, non-alcholic fatty liver disease (nafld), non-alcholic steathohepatitis (nash), diseases caused by abnormal cell proliferation including cancer, psoriasis, and infectious ...
Fatty Liver Patent Pack
Download + patent application PDFs
Fatty Liver Patent Applications
Download + Fatty Liver-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Fatty Liver-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Novel pentadienoyl piperidine derivative and use thereof
Snu R&db Foundation
November 09, 2017 - N°20170320825

The present invention relates to a novel pentadienoyl piperidine derivative, a pharmaceutical composition containing the same for prevention or treatment of metabolic diseases, and a functional food composition using the same for improvement or relief of metabolic diseases. The pentadienoyl piperidine derivative of the present invention inhibits the differentiation of preadipocytes, reduces body weight, visceral fat, blood lipid levels, and ...
Compositions and methods for lipid metabolism disorder
Snu R&db Foundation
November 02, 2017 - N°20170312286

A method for inhibiting a lipid metabolism disorder of a warm-blooded animal includes administering a therapeutically effective amount of a compound being one selected from the group consisting of phosphodiesterase 5 (pde-5) inhibitors of the first type and second type and a statin analogue to a warm-blooded animal suffering from the lipid metabolism disorder. The method may treat the disease selected ...
Methods of treating non-alcoholic steatohepatitis (nash) using cysteamine products
The Regents Of The University Of California
October 26, 2017 - N°20170304233

The disclosure relates, in general, to treatment of fatty liver disorders comprising administering compositions comprising cysteamine products. The disclosure provides administration of enterically coated cysteamine compositions to treat fatty liver disorders, such as non-alcoholic fatty liver disease (nafld) and non-alcoholic steatohepatitis (nash).
Fatty Liver Patent Pack
Download + patent application PDFs
Fatty Liver Patent Applications
Download + Fatty Liver-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Fatty Liver-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Use of a long acting glp-1/glucagon receptor dual agonist for the treatment of non-alcoholic ...
Golden Biotechnology Corporation
October 19, 2017 - N°20170298117

The present invention relates to a pharmaceutical composition for the prevention or treatment of non-alcoholic fatty liver disease including a long-acting glp-1/glucagon receptor dual agonist, and a method for preventing or treatment of non-alcoholic fatty liver disease including administering the composition. The composition of the present invention either has no side effect of weight gain or reduces the side ...
Methods of lowering serum cholesterol
Golden Biotechnology Corporation
October 19, 2017 - N°20170296653

Methods of treating subjects having diseases, disorders, or conditions, including disorders associated with cholesterol homeostasis, responsive to agents modulating kupffer cell function, including methods of administration and dosing regimens associated therewith, are provided. Methods of treating subjects having liver diseases, disorders, or conditions, including non-alcoholic steatohepatitis and non-alcoholic fatty liver disease, with an il-10 agent are also provided.
Composition including extract of dolichos lablab linne as active ingredient for preventing or ameliorating non-alcoholic ...
Golden Biotechnology Corporation
October 19, 2017 - N°20170296607

A health functional food composition and a pharmaceutical composition for preventing or ameliorating a non-alcoholic fatty liver disease include an extract of dolichos lablab linne as an active ingredient. The extract of dolichos lablab linne, being an active ingredient, effectively reduces accumulation of triglyceride in hepatocarcinoma cell line (hepg2). Therefore, the compositions are used for functional foods and medicines for ...
Adeno-associated viral vectors for the gene therapy of metabolic diseases
Universitat Autonoma De Barcelona
October 12, 2017 - N°20170290926

The present invention discloses adeno-associated viral vectors useful in gene therapy methods for the treatment of obesity, insulin resistance, type 2 diabetes, liver cirrhosis and non-alcoholic fatty liver disease (nafld)/non-alcoholic steatohepatitis (nash). The invention also relates to polynucleotides, plasmids, vectors and methods for the production of such adeno-associated viral vectors. The invention also relates to pharmaceutical compositions comprising said vectors.
Composition for preventing or treating hyperlipidemia
Hawon Pharm. Corporation
October 12, 2017 - N°20170290874

A pharmaceutical composition for preventing or treating hyperlipidemia includes a salvia miltiorrhiza extract, a crataegus pinnatifida extract, a polygonum multiflorum extract, and a ligusticum chuanxiong extract, thereby reducing the amounts of serum cholesterol and ldl-cholesterol and increasing the amount of hdl-cholesterol; significantly reduces the amount of serum triglyceride compared with existing statin-based drugs, thereby exhibiting prophylactic and therapeutic effects of ...
Alpha-1 anti-trypsin for treating liver diseases
Hadasit Medical Research Services And Development Ltd.
October 05, 2017 - N°20170281739

Methods of treating liver diseases are provided. Accordingly there is provided a method of treating a liver disease selected from the group consisting of fatty liver disease and chronic liver rejection in a subject in need thereof, wherein said liver disease is not associated with genetic alpha-1 anti-trypsin (aat) deficiency, the method comprising administering to the subject a therapeutically effective ...
Methods of treating fatty liver disease
Genzyme Corporation
October 05, 2017 - N°20170281593

The disclosure provides methods for treating fatty liver disease and associated conditions by inhibiting the synthesis of glucosphingolipids, as exemplified by the use of glucosylceramide synthase substrate analogs.
Fatty Liver Patent Pack
Download + patent application PDFs
Fatty Liver Patent Applications
Download + Fatty Liver-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Fatty Liver-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
2-alkyloxy benzene formyl arylamine compound and pharmaceutical use thereof
Fudan University
September 07, 2017 - N°20170253564

2-alkoxy benzene formyl arylamine compounds and their pharmaceutical salts are disclosed. The compounds can act as sphingomyelin synthase (sms) inhibitors to treat diseases caused by abnormal increasing of sphingomyelin (sm). The pharmaceutically acceptable salts and pharmaceutical compositions of the compounds are used as active ingredients in drugs which can prevent and cure diseases caused by sm level abnormal increase. These ...
Cenicriviroc for the treatment of fibrosis
Tobira Therapeutics ,inc.
August 24, 2017 - N°20170239262

The present disclosure provides methods of treating fibrosis or a fibrotic disease or condition in a subject in need thereof comprising administering to the subject a therapeutically effective amount of cenicriviroc or a salt or solvate thereof. The fibrosis or fibrotic disease may be liver fibrosis, renal fibrosis, non-cirrhotic hepatic fibrosis, associated with non-alcoholic steatohepatitis (nash), non-alcoholic fatty liver disease (...
Nonalcoholic fatty liver disease (nafld) and nonalcoholic steatohepatitis (nash) biomarkers and uses thereof
Somalogic, Inc.
August 10, 2017 - N°20170227550

Methods, compositions, and kits for determining whether a subject has non-alcoholic fatty liver disease (nafld) are provided. Methods, compositions, and kits for determining whether a subject has non-alcoholic steatosis are also provided. Methods, compositions, and kits for determining whether a subject has non-alcoholic steatohepatitis (nash) are also provided.
A peptide therapy to counteract insulin resistance and type 2 diabetes
Indian Institute Of Technology Madras
July 27, 2017 - N°20170209544

Compositions comprising an antagonist of pancreastatin are provided. The beneficial use of the compositions for treating insulin resistance, diabetes, especially type ii diabetes, inflammation, obesity, non-alcoholic fatty liver disease, atherosclerosis and cardiovascular diseases is described as well.
Novel lactic acid bacterium and composition including said lactic acid bacterium
Nitto Pharmaceutical Industries, Ltd.
July 20, 2017 - N°20170202890

The present invention provides a lactobacillus that improves hyperuricemia, fatty liver and a lifestyle-related disease, and a composition containing the lactobacillus.
Prevention and treatment of non-alcoholic fatty liver disease
Ohio University
July 13, 2017 - N°20170196845

Methods for preventing, treating, and/or reducing the risk of developing non-alcoholic fatty liver disease in a subject in need thereof and pharmaceutical compositions for the prevention or treatment of non-alcoholic fatty liver disease. Methods for inhibiting excessive accumulation of fat in liver tissue. The methods include administering to the subject or contacting the liver tissue with a therapeutically effective ...
Bacteroides cect 7771 and the use thereof in the prevention and treatment of excess weight, obesity ...
Consejo Superior De Investigaciones Cientificas
July 06, 2017 - N°20170189456

The invention relates to a strain of bacteroides uniformes with registration number cect 7771, and to the cellular constituents, metabolites and/or secreted molecules thereof. The invention also relates to a composition (nutritional or pharmaceutical) comprising at least one of the previous products. The invention further relates to the use of a strain of bacteroides uniforms, preferably cect 7771, or of the ...
Treatment and prevention of liver disease associated with parenteral nutrition (pn)
Children's Medical Center Corporation
July 06, 2017 - N°20170189365

The present invention is based on the discovery that parenteral nutrition (pn) induced liver disease, e. G. Fatty liver disease, can be prevented and even reversed by administration of primarily omega-3-fatty acid with pn rather than the administration of the standard intravenous lipid emulsions that contain primarily plant derived omega-6 fatty acid. Thus, the present invention provides a method ...
Loading